Retrospective Study to Evaluate the Safety of Duvie in Korean Patients With Type 2 Diabetes Mellitus

CompletedOBSERVATIONAL
Enrollment

2,228

Participants

Timeline

Start Date

January 2, 2019

Primary Completion Date

June 19, 2020

Study Completion Date

June 19, 2020

Conditions
Type2 Diabetes
Interventions
DRUG

Duvie(Lobeglitazone) tab 0.5mg

patients with type 2 diabetes who received lobeglitazone 0.5mg for more than one year between February 1, 2014 and December 20, 2018

Trial Locations (1)

Unknown

Division of Endocrinology and Metabolism, Department of Internal Medicine, Bucheon St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY